Review Article: The Evolving Role of GLP ‐1 Receptor Agonists in Gastroenterology Practice
Alimentary Pharmacology & Therapeutics · 2026-01 · 63 (2) · 203-209
DOI: 10.1111/apt.70450 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 11.11.2025. Verfasst von Sydney Pomenti und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Digestive and Liver Diseases, Columbia University Irving Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Gastrointestinal Diseases, Obesity. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Background
Obesity affects over 40% of the US population and contributes to worse outcomes in a variety of diseases and disorders. Glucagon‐like peptide‐1 receptor agonists have drawn attention for their impact on obesity. With a dense population of receptors throughout the gastrointestinal tract, it is critical to understand the way that glucagon‐like peptide‐1 receptor agonists impact gastrointestinal diseases and disorders.
Aims
To evaluate the expanding role of glucagon‐like peptide‐1 receptor agonists in the management of obesity and gastrointestinal disease, with a focus on therapeutic applications, impact on gastrointestinal cancers, safety profile, and implications for gastroenterology practice.
Methods
We conducted a narrative review of recent clinical trials, cohort studies, and guideline updates through 2025. Evidence was synthesised on efficacy, safety, and clinical implications across gastrointestinal disorders including steatotic liver disease, gastroesophageal reflux, inflammatory bowel disease, short bowel syndrome, and obesity‐associated cancers.
Results
Glucagon‐like peptide‐1 receptor agonists induce substantial and durable weight loss and improve obesity‐related gastrointestinal outcomes. They are approved for steatotic liver disease, with demonstrated histologic and biochemical benefits. Evidence suggests a reduced incidence of several gastrointestinal cancers. The most common adverse events include nausea, vomiting, diarrhoea, constipation, and delayed gastric emptying, which may affect peri‐endoscopic management. Discontinuation rates remain substantial but can be mitigated by careful titration and specialist oversight.
Conclusions
Glucagon‐like peptide‐1 receptor agonists are a critical therapy for obesity and several related gastrointestinal conditions. Gastroenterologists are uniquely positioned to optimize their use, manage adverse events, coordinate multidisciplinary care, and ensure safe and effective integration into practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Digestive and Liver Diseases, Columbia University Irving Medical Center, New York, New York, USA.
- Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: David Katzka, Michael Camilleri
Zitieren
APA
Pomenti, S., Gerber, A., Katzka, D., Camilleri, M., & Hur, C. (2026). Review Article: The Evolving Role of GLP ‐1 Receptor Agonists in Gastroenterology Practice. Alimentary Pharmacology & Therapeutics, 63(2), 203-209. https://doi.org/10.1111/apt.70450
Vancouver
Pomenti S, Gerber A, Katzka D, Camilleri M, Hur C. Review Article: The Evolving Role of GLP ‐1 Receptor Agonists in Gastroenterology Practice. Alimentary Pharmacology & Therapeutics. 2026;63(2):203-209. doi:10.1111/apt.70450
BibTeX
@article{Pomenti2026,
author = {Pomenti, Sydney and Gerber, Annabel and Katzka, David and Camilleri, Michael and Hur, Chin},
title = {Review Article: The Evolving Role of GLP ‐1 Receptor Agonists in Gastroenterology Practice},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {63},
number = {2},
pages = {203--209},
doi = {10.1111/apt.70450}
}
EUVIMED